Cleveland BioLabs to Present at Rodman & Renshaw 17th Annual Global Investment Conference

BUFFALO, NY--(Marketwired - Sep 2, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Rodman & Renshaw 17^th Annual Global Investment Conference, September 8-10, in New York, NY.

Rachel Levine, Vice President of Investor Relations for Cleveland BioLabs, will present the Company's biodefense and oncology programs on September 10 at 1:45 p.m. ET. A live and archived webcast of the Company's presentation will be available on the investor page of the Cleveland BioLabs website at www.cbiolabs.com.

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. The company's proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's most advanced product candidate is entolimod, which is being developed for a biodefense indication and as an immunotherapy for oncology and other indications. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and a joint venture with OJSC Rusnano, Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.